Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone ISM in acute exacerbation of schizophrenia
NCT03160521Phase 3Completed
- Sponsor
- Laboratorios Farmacéuticos ROVI
- Start
- Jun 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of risperidone in schizophrenia (3 arms), sponsored by Laboratorios Farmacéuticos ROVI. Primary endpoint: Positive and Negative Syndrome Scale Total Score Mean Change From Baseline at Day 85. Started Jun 2017; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03160521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03160521.